DMAA SPAC enters $100K convertible bridge as first step of $500K financing; identifies AI/cybersecurity target

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

tnership, L.P., a Delaware limited partnership (the “Operating Partnership” and, together with the Company, the “Borrowers”) extended the maturity date of the Borrowers’ revolving credit facility (the “Revolving Credit Facility”) provided under the Borrowers’ Second Amended and Restated Credit Agreement, dated as of June 30, 2022 (the “Credit Agreement”), by and among the Borrowers, Bank of America, N.A., as administrative agent and lender, and the other agents and lenders party thereto, for a period of six months from June 30, 2026 to December 30, 2026.

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

On May 27, 2026, CPS Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Investors”) for the sale by the Company of 1,200,000 shares (the “Shares”) of its Common Stock, par value $0.01 per share (“Common Stock”), in a registered direct offering (the “Offering”), at a purchase price of $8.00 per share.

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (" Live Oak "), and HB Strategies LLC (" Seller " or " FPA Investor ") entered into an agreement (the " Forward Purchase Agreement ") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the " Forward Purchase Transaction ") in connection with Live Oak’s proposed initial business combination (the " Business Combination ") with Teamshares Inc., a Delaware corporation (" Teamshares " and the surviving public company following consummation of the Business Combination, the " Combined Company "), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the " Merger Agreement ").

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

On May 8, 2026, Synergy CHC Corp. (the “Company”) entered into an equity purchase agreement (the “Purchase Agreement”) with Hudson Global Ventures, LLC (the “Investor”), pursuant to which the Company has the right, but not the obligation, to direct the Investor to purchase up to $36,000,000 of the Company’s common stock

This filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

Comparable filing

On May 7, 2026, Serve Robotics Inc. (the “Company”) and each of Cantor Fitzgerald & Co., Wedbush Securities Inc., Northland Securities, Inc., Ladenburg Thalmann & Co. Inc. and Seaport Global Securities LLC (collectively, the “Agents”) agreed to terminate the Controlled Equity Offering SM Agreement, dated as of March 6, 2025 (the “Prior Sales Agreement”).